SEC-sourced researchBeta
COLL
COLLEGIUM PHARMACEUTICAL, INC
Company comparison ↗
Data passport
- CIK
- 0001267565
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 30, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 566,767,000.0000 | Feb 26, 2026 |
| December 2024 | 631,449,000.0000 | Feb 26, 2026 |
| December 2025 | 780,567,000.0000 | Feb 26, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 780,567,000.0000 | 62,870,000.0000 | 329,323,000.0000 | 1,656,834,000.0000 | 1,355,159,000.0000 | Feb 26, 2026 |
| December 2024 | 631,449,000.0000 | 69,190,000.0000 | 204,980,000.0000 | 1,663,591,000.0000 | 1,434,749,000.0000 | Feb 26, 2026 |
| December 2023 | 566,767,000.0000 | 48,155,000.0000 | 274,749,000.0000 | — | — | Feb 26, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $780.57M | December 2025 | Feb 26, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $631.45M | December 2024 | Feb 26, 2026 | 10-K |
| Net incomeNetIncomeLoss | $62.87M | December 2025 | Feb 26, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $329.32M | December 2025 | Feb 26, 2026 | 10-K |
| Total assetsAssets | $1.66B | December 2025 | Feb 26, 2026 | 10-K |
| Total liabilitiesLiabilities | $1.36B | December 2025 | Feb 26, 2026 | 10-K |